As the largest resource of information specific to women's brain health, we are sure you will find what you are looking for, and promise that you will discover new information.
Published on: February 21, 2012
by Fierce Biotech
With Alzheimer’s disease threatening millions of patients worldwide, the European Commission-funded database that stores 3-D brain scans in the cloud has gained global attention. The so-called neuGRID, which has been tested in Europe, is seeking partners in North America and Asia to support sharing of Alzheimer’s data around the world. The goal is to speed diagnosis of the memory-stealing illness.
Work is afoot to advance a global version of neuGRID dubbed outGRID, and stakeholders from the European Commission and the World Health Organization are meeting this week in Geneva with the assistance of the United Nations, according to a press release. The groups aim to plug neuGRID into the Laboratory of Neuro Imaging (LONI) in the U.S. and CBRAIN in Canada, giving researchers an interoperable system for sharing brain scans.
Alzheimer’s disease begs for better diagnostic and therapeutic options. With 5 million Americans suffering from the disease, many drug and diagnostic outfits are pursuing new products to address this huge market. President Obama has backed a plan to speed effective treatments for Alzheimer’s patients by 2025, and drugmakers such as Pfizer, Johnson & Johnson and Eli Lilly are in late stages of developing new drugs against the disease. Yet the biology of the disease isn’t fully understood, making research efforts such as outGRID important to improving treatment.
“outGRID responds to today’s pressing need for effective computational tools to support Alzheimer’s research,” Kostas Glinos, head of the unit for e-infrastructure at the European Commission’s Directorate General for Information Society, said in a statement. “With the strong commitment of research centers and support of public funds, outGRID should succeed in establishing a global infrastructure that maximizes the use of MRIs and accelerates progress in combating Alzheimer’s, for the benefit of millions of patients and their families.”
A new comprehensive study from Florida State University (FSU) finds no evidence to support the idea that personality changes begin before the clinical onset of mild cognitive impairment (MCI) or dementia. MCI is an intermediate...
On the evening of Monday November 27th, join us for conversation and cocktails with award-winning journalist, editor and author Tina Brown, and Indigo’s CEO Heather Reisman. Hear from Tina Brown about her eight-year tenure at Vanity...
The presence of TAR DNA-binding protein 43 (TDP-43) in the hippocampus on postmortem examination is associated with increased rates of hippocampal atrophy in patients with Alzheimer’s disease (AD), new research suggests. This association was greatest...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.